Abstract: ［Abstract］ ObjectiveTo investigate the value of the eradication of helicobacter pylori（Hpylori） in the treatment of dual antiplatelet therapy after percutaneous coronary stent implantation（PCI）. MethodsAfter PCI, 282 cases with Hpylori infection were randomly divided into group A，group B and group C. One hundred and twentyfive patients without Hpylori infection were treated as control group. All the patients in 4 groups were treated with dual antiplatelet therapy. At the same time group B was treated with pantoprazole for six months, group C was treated with Hpylori eradication and pantoprazole for six months. The symptoms of dyspepsia, upper gastrointestinal hemorrhage （UGH） and major adverse cardiovascular events（MACE）were compared. ResultsFor the incidence of dyspepsia, group A> control group> group B> group C(489% vs 298% vs 191% vs 75%,P＜005)；For UGH incidence, group A> control group, group B>group C(160% vs 65%, 74% vs 11%, P＜005), difference between the control group and Group B was not statistically significant(P＞005). For comparing MACE incidence, there were no statistical difference among 4 groups(P＞005). There was no significant difference in the incidence of UGH in patients with pylori H. eradication failure(67% vs 0%, P＞005).  ConclusionHpylori infection can increase symptoms of dyspepsia and the incidence of UGH within one year after PCI and dual antiplatelet therapy in patients. The Hpylori eradication program containing pantoprazole combined with a half year of pantoprazole therapy can effectively prevent and reduce those symptoms, and does not increase the incidence of MACE. However, whether it can reduces the incidence of MACE needs large samples and longrange observation.

Key words: ［Key words］helicobacter pylori； platelet aggregation inhibitors, compatrative study